


Amendments to the claims

1. (Currently amended) A compound of formula (I):



wherein

R¹ is a phenyl group which may be optionally substituted;

R² is C₁-6alkyl substituted by one to three groups independently selected from OH, oxo, cyano, -S(O)_pR⁴, halogen, C₁-6alkoxy, -NR⁵R⁶, -CONR⁵R⁶, -NCOR⁵, -COOR⁵, -SO₂NR⁵R⁶, -NHSO₂R⁵ and -NHCONHR⁵;

R³ is the group -CO-NH-(CH₂)_q-R⁷ or -NH-CO-R⁸;

R⁴ is selected from hydrogen, C₁-6alkyl, heterocyclyl optionally substituted by C₁-4alkyl, and phenyl wherein the phenyl is optionally substituted by up to two groups independently selected from C₁-6alkoxy, C₁-6alkyl and halogen;

R⁵ and R⁶ are each independently selected from hydrogen and C₁-6alkyl;

when q is 0 to 2, R⁷ is selected from hydrogen, C₁-6alkyl, -C₃-7cycloalkyl, -CONHR⁹, phenyl optionally substituted by R¹¹ and/or R¹², heteroaryl optionally substituted by R¹¹ and/or R¹² and heterocyclyl optionally substituted by R¹¹ and/or R¹², and

when q is 2, R⁷ is additionally selected from C₁-6alkoxy, NHCOR⁹, NHCONHR⁹, NR⁹R¹⁰ and OH;

R⁸ is selected from hydrogen, C₁-6alkyl, C₁-6alkoxy, -(CH₂)_r-C₃-7cycloalkyl, trifluoromethyl, -(CH₂)_sphenyl optionally substituted by R¹³ and/or R¹⁴, -(CH₂)_sheteroaryl optionally substituted by R¹³ and/or R¹⁴, -(CH₂)_sheterocyclyl optionally substituted by R¹³ and/or R¹⁴ and -(CH₂)_sfused bicycyl optionally substituted by R¹³ and/or R¹⁴;

R⁹ is selected from hydrogen, C₁₋₆alkyl and phenyl wherein the phenyl group is optionally substituted by up to two substituents selected from C₁₋₆alkyl and halogen,

R¹⁰ is selected from hydrogen and C₁₋₆alkyl, or

R⁹ and R¹⁰, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic or heteroaryl ring optionally containing one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring may be substituted by up to two C₁₋₆alkyl groups;

R¹¹ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -CONR¹⁰R¹⁵, -NHCOR¹⁵, -SO₂NHR¹⁵, -NHSO₂R¹⁵, halogen, trifluoromethyl, -Z-(CH₂)_t-phenyl optionally substituted by one or more halogen atoms, -Z-(CH₂)_t-heterocyclyl or -Z-(CH₂)_t-heteroaryl wherein the heterocyclyl or heteroaryl group is optionally substituted by one or more substituents selected from C₁₋₆alkyl,

R¹² is selected from C₁₋₆alkyl and halogen, or

when R¹¹ and R¹² are adjacent to each other they may, together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed R¹¹ and R¹² optionally contains one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R¹³ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_r-C₃₋₇cycloalkyl, -CONR¹⁶R¹⁷, -NHCOR¹⁷, -SO₂NHR¹⁶, -NHSO₂R¹⁷, halogen, -(CH₂)_kNR¹⁸R¹⁹, oxy, trifluoromethyl, phenyl optionally substituted by one or more R¹⁴ groups and heteroaryl wherein the heteroaryl is optionally substituted by one or more R¹⁴ groups,

R¹⁴ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl and -NR¹⁸R¹⁹, or

R¹³ and R¹⁴, together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R¹³ and R¹⁴ optionally contains one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R¹⁵ is selected from hydrogen and C₁₋₆alkyl;

R¹⁶ is selected from hydrogen, C₁₋₆alkyl and phenyl wherein the phenyl group is optionally substituted by one or more R¹⁴ groups,

R¹⁷ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁶ and R¹⁷, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R²⁰, wherein the ring is optionally substituted by up to two C₁₋₆alkyl groups;

R¹⁸ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)_r-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁹ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁸ and R¹⁹, together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R²⁰, wherein the ring may contain up to one double bond and the ring is optionally substituted by one or more R²¹ groups;

R²⁰ is selected from hydrogen and methyl;

R²¹ is selected from C₁₋₆alkyl, oxy, -CH₂OC₁₋₆alkyl, trichloromethyl and -N(C₁₋₆alkyl)₂;

U is selected from methyl and halogen;

W is selected from methyl and chlorine;

X and Y are each selected independently from hydrogen, methyl and halogen;

Z is selected from -O- and a bond;

m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C₁₋₆alkyl;

n, p, q, r and t are independently selected from 0, 1 and 2;

s is selected from 0 and 1; and

k is selected from 0, 1, 2 and 3;

or a pharmaceutically acceptable [[derivative]] salt thereof.

2. (original) A compound according to claim 1 wherein R¹ is phenyl.

3. (Previously presented) A compound according to claim 1 wherein R² is C₁₋₄alkyl substituted by one or two OH groups.

4. (Previously presented) A compound according to claim 1 wherein m is 0 or 1.

5. (Previously presented) A compound according to claim 1 wherein R⁴ is -C₃₋₇cycloalkyl.


6. (Currently amended) A compound according to claim 1 which is N^{4'}-benzyl-N³-cyclopropyl-N^{4'}-(2-hydroxyethyl)-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide; N^{4'}-benzyl-N³-cyclopropyl-N^{4'}-(3-hydroxypropyl)-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide;

N³-cyclopropyl-N^{4'}-(2-hydroxyethyl)-6-methyl-N^{4'}-phenyl-1,1'-biphenyl-3,4'-dicarboxamide;

as defined in any one of Examples 1 to 3, or a pharmaceutically acceptable [[derivative]] salt thereof.

7. (Previously presented) A process for preparing a compound according to claim 1 which comprises:

(a) reacting a compound of formula (XXII)




(XXII)

wherein R¹, R², U, W, X, Y, m and n are as defined in claim 1, with a compound of formula (XXIII)




wherein R⁷ and q are as defined in claim 1, under amide forming conditions, optionally converting the acid compound (XXII) to an activated form of the acid before reaction with the amine compound (XXIII);

(b) reacting a compound of formula (XXIV)




(XXIV)

wherein R^3 , U , W , X , Y and n are as defined in claim 1,
with a compound of formula (XXV)



wherein R^1 , R^2 and m are as defined in claim 1,
under amide forming conditions;


(c) reacting a compound of formula (XXVI)



(XXVI)


wherein R^3 , U , W , X , Y and n are as defined in claim 1,
with a compound of formula (XXV) as defined above;

(d) functional group conversion of a compound of formula (XXVII)



wherein R^3 , U , W , X , Y and n are as defined in claim 1 and R^{1A} and R^{2A} are R^1 and R^2 as defined in claim 1 or groups convertible to R^1 and R^2 ,
to give a compound of formula (I); or

(e) reacting a compound of formula (XXVIII)



wherein R^1 , R^2 , U , W , X , Y , m and n are as defined in claim 1,
with a compound of formula (XXIX)



wherein R^8 is as defined in claim 1,

under amide forming conditions, optionally converting the acid compound (XXIX) to an activated form of the acid before reaction with the amine compound (XXVIII).

8. (Currently amended) A pharmaceutical composition comprising at least one compound according to claim 1 or a pharmaceutically [[derivative]] salt thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.

9. (Currently amended) A method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound according to claim 1 or a pharmaceutically acceptable [[derivative]] salt thereof.

10 –11. (cancelled)

12. (new) A compound according to claim 1 wherein R¹ is a phenyl substituted up to three times by halogen; C₁-4alkyl; C₁-4alkoxy; phenoxy optionally substituted by the group A; benzyloxy; hydroxy; cyano; hydroxyC₁-4alkyl; -(CH₂)_h-NHCH₃; -(CH₂)_h-N(CH₃)₂; -(CH₂)_hCONR²²R²³; -(CH₂)_hCO(CH₂)_iNR²²R²³; -(CH₂)_h-CO₂R²²; -(CH₂)_hNR²²COR²³; -(CH₂)_hOCOR²²; -(CH₂)_hOCONR²²R²³; -(CH₂)_hNR²²COOR²³; -(CH₂)_hCOR²²; -(CH₂)_hSO₂NR²²R²³; -(CH₂)_hNR²²SO₂R²³; -SO₂R²²; -(CH₂)_hNR²²R²³; -(CH₂)_hNR²²CONR²²R²³; or -(CH₂)_hCONR²²SO₂R²³;

R²² and R²³ are independently selected from hydrogen; C₁-6alkyl optionally substituted by up to three hydroxy groups; trihalomethyl; benzyl; -(CH₂)_jCOH; -(CH₂)_jNR²⁴R²⁵; or a phenyl optionally substituted by up to three groups selected from C₁-6alkyl or C₁-6alkoxy;

R²⁴ and R²⁵ are independently selected from hydrogen or C₁-4alkyl;

Group A is selected from halogen, -SO₂NH₂, -SO₂-(4-methyl)piperazinyl, -NR²²COC₁-6alkyl or -NR²²SO₂C₁-6alkyl;

h is selected from 0, 1, 2 or 3;

i is selected from 0, 1, 2 and 3; and

j is selected from 2 or 3.

13. (new) A compound according to claim 3 wherein R² is a C₂-3alkyl substituted by one OH group.

14. (new) A compound according to claim 13 wherein R² is -CH₂CH₂OH or -CH₂CH₂CH₂OH.

15. (new) A compound according to claim 1 wherein R³ is -CO-NH-(CH₂)_q-R⁷.

16, (new) A compound according to claim 1 wherein R⁴ is selected from hydrogen, C₁₋₄alkyl and phenyl.

17. (new) A compound according to claim 1 wherein W is methyl.

18. (new) A compound according to claim 1 wherein X and Y are each selected independently from hydrogen, chlorine and fluorine.

19. (new) A compound according to claim 1 wherein Z is a bond.